Allos Therapeutics reports increase in 2006 second-quarter net loss to $7.0 million

By Lisa Kerner

Charlotte, N.C., Aug. 7 - Allos Therapeutics, Inc. reported a net loss of $7.0 million, or $0.13 per share for the three months ended June 30, an increase from the net loss of $5.6 million, or $0.13 per share, for the second quarter of 2005.

For the six months ended June 30, Allos had a net loss of $14.0 million, or $0.25 per share, compared to a net loss of $10.7 million, or $0.29 per share, for the prior-year period.

At June 30, Allos had cash, cash equivalents and investments in marketable securities totaling $43.5 million.

"During the quarter we continued to meet patient recruitment goals for our pivotal phase 3 Enrich trial, which we believe will ensure the completion of our enrollment effort by the end of the third quarter," president and chief executive officer Paul L. Berns said in a company news release.

Also during the quarter, Allos completed the Food and Drug Administrations' Special Protocol Assessment process for its planned phase 2 study in patients with peripheral T-cell lymphoma.

In addition, the company received orphan-drug designation for PDX for the treatment of T-cell lymphoma, officials said.

Allos is a biopharmaceutical company located in Westminster, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.